Advanced search
Publication Cover
International Journal of Radiation Biology Volume 80, 2004 - Issue 11-12
Submit an article Journal homepage
32
Views
3
CrossRef citations to date
0
Altmetric
Article

Antisense radiotherapy: targeting full‐size mdr1 mRNA with 125I‐labelled oligonucleotides

E. K. Gaidamakova Nuclear Medicine Department, National Institutes of Health, Bethesda, MD 20892‐1180, USACorrespondence[email protected]
,
R. D. Neumann Institute of Molecular Biology and Biophysics, Novosibirsk 630117, Russia
&
I. G. Panyutin Nuclear Medicine Department, National Institutes of Health, Bethesda, MD 20892‐1180, USA
Pages 889-893 | Received 04 Jan 2004, Accepted 10 Mar 2004, Published online: 03 Jul 2009

References

  • ECKSTEIN, F., ScnuLz, H. H., RUTERJANS, H., HAAR, W. and MAURER, W., 1972, Stereochemistry of the transesterification step of ribonuclease T 1. Biochemistry, 11, 3507–3512.
  • GAIDAMAKOVA, E. K., NEUMANN, R. D. and PANYCITIN, I. G., 2002, Site-specific strand breaks in RNA produced by 1251 radiodecay. Nucleic Acids Research, 30, 4960–4965.
  • GERMANN, U. A., 1996, P-glycoproteina mediator of multiclrugresistance in tumour cells. European Journal of Cancer, 32A, 927–944.
  • HNATOWICH, D. J., 1999, Antisense and nuclear medicine. Journal of Nuclear Medicine, 40, 693–703.
  • Ho, S. P., BRITTON, D. H., STONE, B. A., BEHRENS, D. L., LEFFET, L. M., Hosss, F. W., MILLER, J. A. and TRAINOR, G. L., 1996, Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Research, 24, 1901–1907.
  • JULIEN, T., FRANKEL, B., LONGO, S., KYLE, M., GIBSON, S., SHILLITOE, E. and RYKEN, T., 2000, Antisense-mediated inhibition of the bc1-2 gene induces apoptosis in human malignant glioma. Surgical Neurology, 53, 360–368; Discussion, 368–369.
  • LOBACHEVSKY, P. N. and MARTIN, R. F., 2000a, Iodine-125 decay in a synthetic oligodeoxynucleotide. I. Fragment size distribution and evaluation of breakage probability. Radiation Research, 153, 263–270.
  • LOBACHEVSKY, P. N. and MARTIN, R. F., 2000b, Iodine-125 decay in a synthetic oligodeoxynucleotide. II. The role of auger electron irradiation compared to charge neutralization in DNA breakage. Radiation Research, 153, 271–278.
  • MARTIN, R. F. and HASELTINE, W. A., 1981, Range of radiochemical damage to DNA with decay of iodine-125. Science, 213, 896–898.
  • PANYUTIN, I. G. and NEUMANN, R. D., 1996, Sequence-specific DNA breaks produced by triplex-directed decay of iodine-125. Acta Oncologica, 35, 817–823.
  • PANYUTIN, I. G. and NEUMANN, R. D., 1997, Radioprobing of DNA: distribution of DNA breaks produced by decay of 1251 incorporated into a triplex-forming oligonucleotide correlates with geometry of the triplex. Nucleic Acids Research, 25, 883–887.
  • PANYUTIN, I. G., WINTERS, T. A., FEINENDEGEN, L. E. and NEUMANN, R. D., 2000, Development of DNA-based radiopharmaceuticals carrying Auger-electron emitters for anti-gene radiotherapy. Quarterly Journal of Nuclear Medicine, 44, 256–267.
  • PASTAN, I., GOTTESMAN, M. M., UEDA, K., LOVELACE, E., RUTHERFORD, A. V. and WILLINGHAM, M. C., 1988, A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proceedings of the National Academy of Sciences, USA, 85, 4486–4490.
  • SHANGARY, S. and JouNsoN, D. E., 2003, Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bc1-2 protein family. Leukemia, 17, 1470–1481.
  • UEDA, K., CLARK, D. P., CHEN, C. J., RONINSON, I. B., GOTT'ESMAN, M. M. and PASTAN, I., 1987, The human multidrug resistance (mdrl) gene. cDNA cloning and transcription initiation. Journal of Biological Chemistry, 262, 505–508.
  • VoLm, M., 1998, Multidrug resistance and its reversal. Anticancer Research, 18, 2905–2917.
  • WEBB, A., CUNNINGHAM, D., COTTER, F., CLARKE, P. A., DI STEFANO, F., Ross, P., CORBO, M. and DZIEWANOWSKA, Z., 1997, BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349, 1137–1141.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.